AstraZeneca raises full-year revenue guidance.

NORDIC BUSINESS REPORT-July 29, 2022-AstraZeneca raises full-year revenue guidance

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Pharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) reported on Friday a 48% increase in revenue to USD22.2bn for the first half of 2022.

Profit after tax fell to USD748m, from USD2.1bn in the first six months of 2021.

However, excluding the impact of the Alexion acquisition, exchange rates and other one-off costs, operating profit was 71% higher at USD1.4bn.

AstraZeneca's revenue from COVID-19 medicines in 2022 is anticipated to be broadly flat versus 2021, with growth in Evusheld...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT